Late-onset Alzheimer's Disease
GPTKB entity
Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:psychologist
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:AD_Genetics
|
| gptkbp:affects |
older adults
|
| gptkbp:clinical_trial |
ongoing studies
failed trials |
| gptkbp:community_impact |
increased demand for services
need for trained professionals |
| gptkbp:current_use |
gptkb:historical_event
vascular dementia |
| gptkbp:economic_impact |
cost of care
loss of productivity |
| gptkbp:future_plans |
preventive strategies
early detection methods |
| gptkbp:healthcare |
global health concern
|
| https://www.w3.org/2000/01/rdf-schema#label |
Late-onset Alzheimer's Disease
|
| gptkbp:impact |
gptkb:healthcare_organization
caregivers |
| gptkbp:is_popular_in |
most common form of dementia
|
| gptkbp:number_of_stages |
moderate
mild severe |
| gptkbp:number_of_teams |
gradual
|
| gptkbp:personal_life |
social isolation
smoking poor diet physical inactivity |
| gptkbp:public_awareness |
gptkb:Alzheimer's_Awareness_Day
gptkb:World_Alzheimer's_Month |
| gptkbp:research_focus |
gptkb:Alzheimer's_Drug_Discovery_Foundation
gptkb:Alzheimer's_Research_UK biomarkers genetic factors treatment options |
| gptkbp:risk_factor |
gptkb:APOE_ε4_allele
age family history |
| gptkbp:social_responsibility |
gptkb:DSM-5
clinical assessment neuroimaging NIA-AA criteria |
| gptkbp:supports |
gptkb:Alzheimer's_Association
support groups |
| gptkbp:symbol |
misplacing items
withdrawal from social activities changes in mood and personality difficulty performing familiar tasks |
| gptkbp:symptoms |
cognitive decline
memory loss disorientation difficulty with language |
| gptkbp:treatment |
medications
cognitive therapies pharmacological interventions non-pharmacological interventions |